307 related articles for article (PubMed ID: 12091357)
21. Antitumor effects of ajulemic acid (CT3), a synthetic non-psychoactive cannabinoid.
Recht LD; Salmonsen R; Rosetti R; Jang T; Pipia G; Kubiatowski T; Karim P; Ross AH; Zurier R; Litofsky NS; Burstein S
Biochem Pharmacol; 2001 Sep; 62(6):755-63. PubMed ID: 11551521
[TBL] [Abstract][Full Text] [Related]
22. (-)-Delta9-tetrahydrocannabinol antagonizes the peripheral cannabinoid receptor-mediated inhibition of adenylyl cyclase.
Bayewitch M; Rhee MH; Avidor-Reiss T; Breuer A; Mechoulam R; Vogel Z
J Biol Chem; 1996 Apr; 271(17):9902-5. PubMed ID: 8626625
[TBL] [Abstract][Full Text] [Related]
23. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.
Pertwee RG
Br J Pharmacol; 2008 Jan; 153(2):199-215. PubMed ID: 17828291
[TBL] [Abstract][Full Text] [Related]
24. Suppression of nerve growth factor Trk receptors and prolactin receptors by endocannabinoids leads to inhibition of human breast and prostate cancer cell proliferation.
Melck D; De Petrocellis L; Orlando P; Bisogno T; Laezza C; Bifulco M; Di Marzo V
Endocrinology; 2000 Jan; 141(1):118-26. PubMed ID: 10614630
[TBL] [Abstract][Full Text] [Related]
25. Δ
Shang VC; Kendall DA; Roberts RE
Biochem Pharmacol; 2016 Nov; 120():63-71. PubMed ID: 27641813
[TBL] [Abstract][Full Text] [Related]
26. CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain.
Clayton N; Marshall FH; Bountra C; O'Shaughnessy CT
Pain; 2002 Apr; 96(3):253-260. PubMed ID: 11972997
[TBL] [Abstract][Full Text] [Related]
27. Delta-9-tetrahydrocannabinol inhibits antitumor immunity by a CB2 receptor-mediated, cytokine-dependent pathway.
Zhu LX; Sharma S; Stolina M; Gardner B; Roth MD; Tashkin DP; Dubinett SM
J Immunol; 2000 Jul; 165(1):373-80. PubMed ID: 10861074
[TBL] [Abstract][Full Text] [Related]
28. CB1 cannabinoid receptor-mediated neurite remodeling in mouse neuroblastoma N1E-115 cells.
Zhou D; Song ZH
J Neurosci Res; 2001 Aug; 65(4):346-53. PubMed ID: 11494371
[TBL] [Abstract][Full Text] [Related]
29. The cannabinoid delta(9)-tetrahydrocannabinol inhibits RAS-MAPK and PI3K-AKT survival signalling and induces BAD-mediated apoptosis in colorectal cancer cells.
Greenhough A; Patsos HA; Williams AC; Paraskeva C
Int J Cancer; 2007 Nov; 121(10):2172-80. PubMed ID: 17583570
[TBL] [Abstract][Full Text] [Related]
30. Dronabinol has preferential antileukemic activity in acute lymphoblastic and myeloid leukemia with lymphoid differentiation patterns.
Kampa-Schittenhelm KM; Salitzky O; Akmut F; Illing B; Kanz L; Salih HR; Schittenhelm MM
BMC Cancer; 2016 Jan; 16():25. PubMed ID: 26775260
[TBL] [Abstract][Full Text] [Related]
31. The preimplantation mouse embryo is a target for cannabinoid ligand-receptor signaling.
Paria BC; Das SK; Dey SK
Proc Natl Acad Sci U S A; 1995 Oct; 92(21):9460-4. PubMed ID: 7568154
[TBL] [Abstract][Full Text] [Related]
32. Involvement of central and peripheral cannabinoid receptors on antinociceptive effect of tetrahydrocannabinol in muscle pain.
Bagüés A; Martín MI; Sánchez-Robles EM
Eur J Pharmacol; 2014 Dec; 745():69-75. PubMed ID: 25446925
[TBL] [Abstract][Full Text] [Related]
33. Cannabinoid receptors and their endogenous agonist, anandamide.
Axelrod J; Felder CC
Neurochem Res; 1998 May; 23(5):575-81. PubMed ID: 9566594
[TBL] [Abstract][Full Text] [Related]
34. Finding order in chemical chaos - Continuing characterization of synthetic cannabinoid receptor agonists.
Marusich JA; Wiley JL; Lefever TW; Patel PR; Thomas BF
Neuropharmacology; 2018 May; 134(Pt A):73-81. PubMed ID: 29113898
[TBL] [Abstract][Full Text] [Related]
35. Behavioral effects of cannabinoid agents in animals.
Chaperon F; Thiébot MH
Crit Rev Neurobiol; 1999; 13(3):243-81. PubMed ID: 10803637
[TBL] [Abstract][Full Text] [Related]
36. Cannabinoid receptor expression in non-small cell lung cancer. Effectiveness of tetrahydrocannabinol and cannabidiol inhibiting cell proliferation and epithelial-mesenchymal transition in vitro.
Milian L; Mata M; Alcacer J; Oliver M; Sancho-Tello M; Martín de Llano JJ; Camps C; Galbis J; Carretero J; Carda C
PLoS One; 2020; 15(2):e0228909. PubMed ID: 32049991
[TBL] [Abstract][Full Text] [Related]
37. Cannabinoid inhibition of the processing of intact lysozyme by macrophages: evidence for CB2 receptor participation.
McCoy KL; Matveyeva M; Carlisle SJ; Cabral GA
J Pharmacol Exp Ther; 1999 Jun; 289(3):1620-5. PubMed ID: 10336560
[TBL] [Abstract][Full Text] [Related]
38. Perinatal exposure to Δ9-tetrahydrocannabinol triggers profound defects in T cell differentiation and function in fetal and postnatal stages of life, including decreased responsiveness to HIV antigens.
Lombard C; Hegde VL; Nagarkatti M; Nagarkatti PS
J Pharmacol Exp Ther; 2011 Nov; 339(2):607-17. PubMed ID: 21831965
[TBL] [Abstract][Full Text] [Related]
39. Delta 9-tetrahydrocannabinol and cannabinol activate capsaicin-sensitive sensory nerves via a CB1 and CB2 cannabinoid receptor-independent mechanism.
Zygmunt PM; Andersson DA; Hogestatt ED
J Neurosci; 2002 Jun; 22(11):4720-7. PubMed ID: 12040079
[TBL] [Abstract][Full Text] [Related]
40. Δ⁹-Tetrahydrocannabinol attenuates allogeneic host-versus-graft response and delays skin graft rejection through activation of cannabinoid receptor 1 and induction of myeloid-derived suppressor cells.
Sido JM; Nagarkatti PS; Nagarkatti M
J Leukoc Biol; 2015 Sep; 98(3):435-47. PubMed ID: 26034207
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
